3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
9
Prostatic Neoplasms
4
Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Stomach Neoplasms
2
Pancreatic Neoplasms
2
Lymphoma
2
Hemorrhage
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Thromboembolism
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cyst
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neurotoxicity Syndromes
1
Myofibroma
1
Multiple Myeloma
1
Metabolic Diseases
1
Melanoma
1
Interventions
Etoposide
34
Carboplatin
31
Topotecan
24
Cisplatin
21
atezolizumab
11
PM 01183
8
durvalumab
7
Irinotecan
7
amrubicin
5
PE regimen
4
AMG 757
4
rovalpituzumab tesirine
3
pembrolizumab
3
Magnetic Resonance Spectroscopy
3
Dexamethasone
3
tremelimumab
2
tislelizumab
2
etoposide phosphate
2
apatinib
2
Vitamin E
2
Tiragolumab
2
Specimen Handling
2
Radiosurgery
2
RRx-001
2
Paclitaxel
2
Memantine
2
Injections
2
EC regimen
2
trilaciclib
1
toripalimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Small Cell Lung Carcinoma
×
Saline Solution
×
Clear all
NCT03066778
2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3
Completed
453 enrolled
23 charts